BioCardia Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Feb 13, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: BCDA
TL;DR
BioCardia filed an 8-K on 2/13/25, mostly procedural stuff, check full doc for news.
AI Summary
On February 13, 2025, BioCardia, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific new material events, financial figures, or significant business updates were detailed in the provided text excerpt.
Why It Matters
This filing indicates BioCardia, Inc. is meeting its regulatory reporting obligations. Investors should review the full filing for any material updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without immediate disclosed material events, suggesting low immediate risk from this specific filing.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- February 13, 2025 (date) — Date of earliest event reported
- 320 Soquel Way (location) — Principal executive offices address
- Sunnyvale, California (location) — Principal executive offices city and state
- 001-38999 (other) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing by BioCardia, Inc.?
The filing is primarily related to "Other Events" and "Financial Statements and Exhibits" as per the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated February 13, 2025.
What is BioCardia, Inc.'s principal executive office address?
The principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
What is BioCardia, Inc.'s SEC file number?
BioCardia, Inc.'s SEC file number is 001-38999.
What is the SIC code for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code for BioCardia, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-02-13 08:30:21
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20250213_8k.htm (8-K) — 24KB
- ex_777822.htm (EX-99.1) — 19KB
- 0001437749-25-003677.txt ( ) — 178KB
- bcda-20250213.xsd (EX-101.SCH) — 3KB
- bcda-20250213_def.xml (EX-101.DEF) — 11KB
- bcda-20250213_lab.xml (EX-101.LAB) — 15KB
- bcda-20250213_pre.xml (EX-101.PRE) — 11KB
- bcda20250213_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 13, 2025, BioCardia, Inc. (the "Company") issued a press release announcing the completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction (HFrEF) and is believed to be the world's first prospective trial of allogeneic mesenchymal stem cells (MSC) intended for treating HFrEF patients having elevated markers of heart stress and systemic inflammation. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated February 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: February 13, 2025